SUMMARY

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• Case reports of patients with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with TREMFYA are summarized below.^1,2 

CLINICAL DATA

• Ito et al (2024)¹ reported a case of a male patient treated with TREMFYA for SAPHO syndrome involving the unilateral femur.
  • A 35-year-old male presented with right thigh pain that started 2 years prior to the visit and a history of palmoplantar pustulosis with a low risk of infection. He was diagnosed with SAPHO syndrome and was initially prescribed salazosulfapyridine and methotrexate. However, these treatments were ineffective.
  • TREMFYA and alendronate were also attempted with no improvement in femur pain.
  • Eight years after the initial diagnosis, the patient was started on infliximab. The pain decreased without new skin or bone lesions. X-rays of the femur showed sclerosis with no progressive bone destruction.
• Falkenhain-Lopez et al (2022)² reported 6 cases of patients with SAPHO syndrome. One of those patients was treated with TREMFYA after the previous treatments failed. 
  • A 21-year-old male presented with a refractory case of SAPHO syndrome. The patient had severe acne and acne fulminans as the cutaneous manifestation, and bilateral sacroiliitis confirmed by pelvic radiography, negative human leukocyte antigen B27 (HLA B27), as the osteoarticular manifestations.
  • Previous treatments included doxycycline, methotrexate, dapsone, isotretinoin, adalimumab, apremilast, secukinumab, and ixekizumab.
  • The patient was initiated on TREMFYA 100 mg subcutaneous every 4 weeks and prednisone 10 mg daily. Partial cutaneous remission and complete osteoarticular response were achieved in the patient after 3 doses of TREMFYA, with sustained severe acne control at 8 months. No data of longer-term efficacy was available at the time of the case report.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 2 April 2025.